Copeptin in COVID-19

NCT05249751 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2022-02-22

No results posted yet for this study

Summary

This study aimed to investigate the change in serum level of copeptin, a neuroendocrine biomarker, in differentiation between mild-moderate and severe COVID-19 cases on admission time and to find its diagnostic potential.

Conditions

Interventions

DIAGNOSTIC_TEST

Assessement of serum copeptin by ELISA technique

Assessement of serum copeptin by ELISA technique

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-20
Primary Completion
2021-08-31
Completion
2021-09-10

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05249751 on ClinicalTrials.gov